Tech ID: 91-02
Summary
The specificity of T-cell receptor to an antigen is determined by the five variable elements of the a and ß chains. Research scientists at National Jewish Health have developed a method to produce monoclonal antibodies against any of the five variable elements of human T-cell receptor. This method relies on the transfection of human/mouse hybrid T-cell receptor a or ß chains genes into a mouse T-cell hybridoma lacking an endogenous a or b chain gene.
Potential Applications
- Research reagents.
- Monoclonal antibodies for therapeutic use.
Advantages of Invention
- Simple method
- Method adaptable to any of the five variable elements of the human T-cell receptor.
State of Development
Scientists have demonstrated that using this method:
- hVß elements can be expressed on the surface of mouse T-cell hybridomas.
- The transfected T-cell hybrids are excellent immunogens in mice for hVß.
- Monoclonal antibodies against hVß13.1 and -13.2 can be raised and be used for the measurements of Vß13.1 and -13.2 in humans.
Licensing Potential
Available for licensing on a non-exclusive basis.
Patent Status
French Patent #0542897.
Inventors
Yongwon Choi, PhD, John Kappler, PhD and Philippa Marrack, PhD
Publication
- Choi et al. Proc Natl Acad Sci U S A. 1991 Oct 1; 88(19):8357-61. PMID: 1656442
For Further Information, Contact:
Emmanuel Hilaire, PhD
Director
Technology Transfer Office
National Jewish Health
1400 Jackson Street, Room M206b
Denver, CO 80206
Voice: (303) 398-1262
Fax: (303) 270-2352
HilaireE@njhealth.org
